Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
IRS2 is a key cytoplasmic signaling molecule that mediates the effects of insulin, insulin-like growth factor 1 (IGF1), and other cytokines. It acts as a molecular adaptor between various receptor tyrosine kinases—such as the insulin receptor and IGF1R—and downstream effectors in multiple cellular pathways. Upon stimulation by its upstream receptors, IRS2 is phosphorylated on tyrosine residues, enabling it to recruit SH2 domain-containing proteins and propagate intracellular signals essential for metabolic regulation, cell growth, survival, proliferation, and differentiation. Dysregulation of IRS2 is implicated in diseases such as type 2 diabetes, PCOS and cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Insulin Receptor Substrate 2 (IRS2).